Purple Biotech Ltd Revenue Growth Rates (PPBT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Purple Biotech Ltd  (NASDAQ: PPBT)
 

PPBT's Revenue Growth by Quarter and Year

Purple Biotech Ltd's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PPBT Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December 0.00
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 0.00

PPBTs Annual Revenue
Purple Biotech Ltd's Revenue in the fiscal year 2025 $ 0.04 millions
Purple Biotech Ltd's Revenue in the fiscal year 2024 $ 0.04 millions
Purple Biotech Ltd's Revenue in the fiscal year 2023 $ 0.06 millions
Purple Biotech Ltd's Revenue in the fiscal year 2022 $ 0.07 millions
Purple Biotech Ltd's Revenue in the fiscal year 2021 $ 0.08 millions




PPBT Revenue fourth quarter 2024 Y/Y Growth Comment
Purple Biotech Ltd in the fourth quarter 2024 recorded of $ 0.00 millions.

Looking into fourth quarter 2024 results within Major Pharmaceutical Preparations industry 239 other companies have achieved higher Revenue growth. While Purple Biotech Ltd' s Revenue no change of 0% ranks overall at the positon no. 4554 in the fourth quarter 2024.


PPBT Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - - - 0 %
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Purple Biotech Ltd's fourth quarter 2024 Revenue $ 0.00 millions PPBT's Income Statement
Purple Biotech Ltd's fourth quarter 2023 Revenue $ 0.00 millions Quarterly PPBT's Income Statement


PPBT Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   - - - -


Back to PPBT Growth rate Comparisons >> Back to PPBT Growth rate Comparisons >>


Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #240
Healthcare Sector #632
Overall #4554

Revenue Y/Y Growth Statistics
High Average Low
900 % 93.08 % -92.1 %
(Dec 31 2018)   (Dec 31 2021)
Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #240
Healthcare Sector #632
Overall #4554
Revenue Y/Y Growth Statistics
High Average Low
900 % 93.08 % -92.1 %
(Dec 31 2018)   (Dec 31 2021)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Purple Biotech Ltd's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PPBT's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PPBT's IV. Quarter Q/Q Revenue Comment


Purple Biotech Ltd's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 0.04 $ 0.04 $ 0.06 $ 0.07 $ 0.08
Y / Y Revenue Growth (TTM) -4.88 % -26.79 % -16.42 % -15.19 % -92.1 %
Year on Year Revenue Growth Overall Ranking # 4554 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -4.88 % -26.79 % -16.42 % -15.19 % -92.1 %
Seq. Revenue Growth (TTM) Overall Ranking # 4554 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
Purple Biotech Ltd showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2024. If the fiscal year would end in Dec 31 2025, Purple Biotech Ltd's annual Revenue drop would be -4.88% year on year to $0 millions.

In the Healthcare sector 631 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 4554.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 240
Healthcare Sector # 632
Overall # 4554

Revenue TTM Y/Y Growth Statistics
High Average Low
900 %
 93.08 %
-92.1 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 240
Sector # 632
S&P 500 # 4554
Cumulative Revenue growth Comment
Purple Biotech Ltd showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2024. If the fiscal year would end in Dec 31 2025, Purple Biotech Ltd's annual Revenue drop would be -4.88% year on year to $0 millions.

In the Healthcare sector 631 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 4554.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 240
Healthcare Sector # 632
Overall # 4554

Revenue TTM Y/Y Growth Statistics
High Average Low
900 %
93.08 %
-92.1 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 240
Sector # 632
S&P 500 # 4554




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PPBT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Dec 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2024
Adapthealth Corp -0.19%$ -0.185 millions
Bioaffinity Technologies Inc -0.26%$ -0.260 millions
Organon and Co -0.38%$ -0.375 millions
Royalty Pharma Plc-0.41%$ -0.407 millions
Carlisle Companies Incorporated-0.41%$ -0.408 millions
Silo Pharma Inc-0.41%$ -0.409 millions
Shl Telemedicine Ltd-0.52%$ -0.519 millions
Cytek Biosciences Inc -0.59%$ -0.586 millions
Kronos Bio Inc -0.70%$ -0.700 millions
Koninklijke Philips Nv-0.81%$ -0.815 millions
Enhabit Inc -0.92%$ -0.921 millions
Charles River Laboratories International inc -1.08%$ -1.078 millions
Elanco Animal Health Incorporated-1.45%$ -1.449 millions
Illumina Inc -1.60%$ -1.604 millions
Perrigo Company Plc-1.62%$ -1.616 millions
Fonar Corporation-1.72%$ -1.717 millions
Quipt Home Medical Corp -1.90%$ -1.905 millions
Bio rad Laboratories Inc -1.91%$ -1.910 millions
Surmodics Inc -2.06%$ -2.062 millions
Avantor Inc -2.10%$ -2.101 millions
Petvivo Holdings Inc -2.11%$ -2.111 millions
Iridex Corp-2.15%$ -2.153 millions
Assertio Holdings inc -2.43%$ -2.431 millions
Apyx Medical Corp-2.58%$ -2.578 millions
Bioxcel Therapeutics Inc -2.66%$ -2.660 millions
Zynex inc -2.66%$ -2.665 millions
Nrc Health-2.88%$ -2.879 millions
Teladoc Health Inc -3.03%$ -3.033 millions
Orchestra Biomed Holdings Inc -3.44%$ -3.435 millions
Xenetic Biosciences Inc -3.45%$ -3.449 millions


About Purple Biotech Ltd Revenue Growth Rates (PPBT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Purple Biotech Ltd (CIK 1614744).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-26-031365
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Purple Biotech Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.